- Home
- NXP vs MYGN Comparison
NXP vs MYGN Comparison
Compare NXP & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXP
- MYGN
- Stock Information
- Founded
- NXP 1992
- MYGN 1991
- Country
- NXP United States
- MYGN United States
- Employees
- NXP N/A
- MYGN N/A
- Industry
- NXP Trusts Except Educational Religious and Charitable
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NXP Finance
- MYGN Health Care
- Exchange
- NXP Nasdaq
- MYGN Nasdaq
- Market Cap
- NXP 730.9M
- MYGN 744.7M
- IPO Year
- NXP N/A
- MYGN 1995
- Fundamental
- Price
- NXP $14.08
- MYGN $4.88
- Analyst Decision
- NXP
- MYGN Hold
- Analyst Count
- NXP 0
- MYGN 16
- Target Price
- NXP N/A
- MYGN $15.47
- AVG Volume (30 Days)
- NXP 70.0K
- MYGN 3.4M
- Earning Date
- NXP 01-01-0001
- MYGN 05-06-2025
- Dividend Yield
- NXP 4.04%
- MYGN N/A
- EPS Growth
- NXP N/A
- MYGN N/A
- EPS
- NXP 0.54
- MYGN N/A
- Revenue
- NXP N/A
- MYGN $831,300,000.00
- Revenue This Year
- NXP N/A
- MYGN N/A
- Revenue Next Year
- NXP N/A
- MYGN $6.42
- P/E Ratio
- NXP $26.81
- MYGN N/A
- Revenue Growth
- NXP N/A
- MYGN 7.38
- 52 Week Low
- NXP $12.91
- MYGN $3.81
- 52 Week High
- NXP $14.89
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- NXP 52.00
- MYGN 45.75
- Support Level
- NXP $13.94
- MYGN $3.99
- Resistance Level
- NXP $14.15
- MYGN $4.38
- Average True Range (ATR)
- NXP 0.12
- MYGN 0.28
- MACD
- NXP 0.00
- MYGN 0.21
- Stochastic Oscillator
- NXP 63.24
- MYGN 93.04
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a diversified closed-end investment company. It seeks to provide current income and stable dividends, exempt from regular federal and designated state income taxes, consistent with the preservation of capital by investing primarily in a portfolio of municipal obligations.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.